AGENUS INC Number of Reportable Segments
AGENUS INC (AGEN) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-07
- AGENUS INC number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- AGENUS INC number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- AGENUS INC number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- AGENUS INC number of reportable segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- AGENUS INC number of reportable segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- AGENUS INC number of reportable segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-17 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-14 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-16 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-16 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-03-16 | |||
| 2018-12-31 | 1.00 Segment 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |